Actavis, Inc. (NYSE:ACT)

CAPS Rating: 4 out of 5

The Company is engaged in the development, manufacture, marketing, sale and distribution of brand and off-patent pharmaceutical products.

Recs

0
Player Avatar pchop123 (76.56) Submitted: 7/14/2012 3:45:24 PM : Outperform Start Price: $76.97 ACT Score: +4.30

LIke their business model and prospects going forward

Report this Post Reply

Featured Broker Partners


Advertisement